Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Average Rating of “Hold” by Brokerages

Revance Therapeutics, Inc. (NASDAQ:RVNC) has received a consensus rating of “Hold” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $10.29.

Several research firms have issued reports on RVNC. HC Wainwright lowered shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 13th. Stifel Nicolaus cut their price objective on shares of Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Barclays restated an “equal weight” rating and issued a $7.00 price objective (down from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. William Blair reiterated a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Finally, Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a research note on Monday, August 12th.

Hedge Funds Weigh In On Revance Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Certuity LLC purchased a new position in shares of Revance Therapeutics in the second quarter worth about $26,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Revance Therapeutics in the second quarter valued at approximately $33,000. Hsbc Holdings PLC purchased a new stake in Revance Therapeutics during the 2nd quarter worth approximately $38,000. Nisa Investment Advisors LLC lifted its holdings in Revance Therapeutics by 2,167.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 18,077 shares in the last quarter. Finally, Creative Planning purchased a new position in Revance Therapeutics in the third quarter valued at $56,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Revance Therapeutics Price Performance

Shares of NASDAQ RVNC opened at $5.30 on Friday. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $9.74. The business has a fifty day moving average price of $5.89 and a 200 day moving average price of $4.30. The stock has a market capitalization of $555.55 million, a P/E ratio of -1.66 and a beta of 0.98.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.12. The firm had revenue of $65.39 million during the quarter, compared to the consensus estimate of $66.30 million. During the same quarter in the prior year, the business posted ($0.80) earnings per share. The firm’s quarterly revenue was up 20.2% on a year-over-year basis. As a group, equities research analysts anticipate that Revance Therapeutics will post -1.53 earnings per share for the current fiscal year.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.